A Phase Ib/Ii Open-Label Study Of Tazemetostat (Taz) Plus Enzalutamide (E) Or Abiraterone/Prednisone (A/P) In Chemotherapy-Naive Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要